CRYSVITA® (burosumab-twza) is the first and only FDA-approved therapy targeting excess fibroblast growth factor 23 (FGF23) in patients with tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
CRYSVITA for TIO
Tumor-induced osteomalacia is an acquired form of hypophosphatemia resulting in osteomalacia. TIO may also be called oncogenic osteomalacia.
Learn About TIOLearn about CRYSVITA’s proposed mechanism of action (MOA) on excess fibroblast growth factor 23 (FGF23)
View the Proposed MOA
UltraCare® Patient Services for CRYSVITA is a program that provides information about how you and your patients can access CRYSVITA. Our services are designed to help patients and caregivers understand their insurance coverage and determine their eligibility for financial and patient assistance programs.
Visit UltraCare
